Prime Medicine, Inc. Logo

Prime Medicine, Inc.

Developing 'search and replace' gene editing therapies to treat genetic disorders.

PRME | NDAQ

Overview

Corporate Details

ISIN(s):
US74168J1016
LEI:
Country:
United States of America
Address:
60 FIRST ST., 2141 CAMBRIDGE
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Prime Medicine, Inc. is a biotechnology company focused on developing and delivering potentially curative gene editing therapies. The company utilizes its proprietary Prime Editing platform, a next-generation technology designed to function like a genetic 'search and replace' tool. This approach allows for the precise correction of faulty DNA by replacing it with a correct sequence, thereby addressing the root cause of disease. Prime Medicine is advancing a pipeline of therapeutic candidates aimed at treating a wide range of debilitating genetic disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prime Medicine, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prime Medicine, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prime Medicine, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America MBRX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Moolec Science SA Logo
Uses Molecular Farming to grow animal proteins in plants for food, feed, and supplement industries.
United States of America MLEC
MoonLake Immunotherapeutics Logo
Developing Nanobody therapies for inflammatory and immunologic diseases like psoriatic arthritis.
United States of America MLTX
Mural Oncology plc Logo
Developing cytokine-based immunotherapies for difficult-to-treat cancers and solid tumors.
United States of America MURA
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
Ireland MURA
N2OFF, Inc. Logo
Sustainable agri-tech for food preservation, emissions reduction, and renewable energy.
United States of America NITO

Talk to a Data Expert

Have a question? We'll get back to you promptly.